How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
Overview
Affiliations
Medication non-adherence is common among patients with systemic lupus erythematosus (SLE) and may lead to poor clinical outcomes. Our aim was to identify influenceable contributors to medication non-adherence and suggest interventions that could increase adherence. Patients with SLE from two Swedish tertiary referral centres ( = 205) participated in a survey assessing self-reported adherence to medications. Responses were used to select patients for qualitative interviews ( = 15). Verbatim interview transcripts were analysed by two researchers using content analysis methodology. The median age of the interviewees was 32 years, 87% were women, and their median SLE duration was nine years. Reasons for non-adherence were complex and multifaceted; we categorised them thematically into (i) patient-related (e.g., unintentional non-adherence due to forgetfulness or intentional non-adherence due to disbelief in medications); (ii) healthcare-related (e.g., untrustworthy relationship with the treating physician, authority fear, and poor information about the prescribed medications or the disease); (iii) medication-related (e.g., fear of side-effects); and (iv) disease-related reasons (e.g., lacking acceptance of a chronic illness or perceived disease quiescence). Interventions identified that healthcare could implement to improve patient adherence to medications included (i) increased communication between healthcare professionals and patients; (ii) patient education; (iii) accessible healthcare, preferably with the same personnel; (iv) well-coordinated transition from paediatric to adult care; (v) regularity in addressing adherence to medications; (vi) psychological support; and (vii) involvement of family members or people who are close to the patient.
Parodis I, Wincup C, Touma Z, Andersen J, Strand V, Sjowall C RMD Open. 2025; 11(1).
PMID: 40055003 PMC: 11891533. DOI: 10.1136/rmdopen-2024-005400.
Harry O, Richard B, Taxter A, Skelton J J Clin Rheumatol. 2024; 30(8):332-335.
PMID: 39352307 PMC: 11747896. DOI: 10.1097/RHU.0000000000002142.
Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.
Nikolopoulos D, Lourenco M, Depascale R, Triantafyllias K, Parodis I Mediterr J Rheumatol. 2024; 35(Suppl 2):328-341.
PMID: 39193182 PMC: 11345603. DOI: 10.31138/mjr.290424.eci.
Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J Rheumatol Int. 2024; 44(7):1233-1244.
PMID: 38609655 PMC: 11178609. DOI: 10.1007/s00296-024-05562-z.
Walhelm T, Wirestam L, Enman Y, Parodis I, Sjowall C J Clin Med. 2024; 13(5).
PMID: 38592294 PMC: 10934232. DOI: 10.3390/jcm13051485.